From Self-sufficiency
Jump to: navigation, search
Olmesartan medoxomil
Systematic (IUPAC) name
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate
Clinical data
  • C (D if used in second or third trimester)
Routes of
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 26%
Metabolism Hepatic (cannot be removed by hemodialysis)
Biological half-life 13 hours
Excretion Renal 40%, biliary 60%
CAS Number 144689-63-4
ATC code C09CA08 (WHO)
C09DA08 (with diuretics)
C09DB02 (with amlodipine)
PubChem CID 130881
DrugBank APRD00223
Chemical data
Formula C29H30N6O6
Molar mass 558.585 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

olmesartan medoxomil (trade names Benicar (US), Olmetec (EU)) is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug olmesartan medoxomil is marketed worldwide by Daiichi Sankyo and in India by Zydus Cadila under the trade name Olmy and by Ranbaxy Laboratories Ltd. under the trade name Olvance.


Olmesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.[1]



Adverse effects

Adverse effects include headache, dizziness, diarrhea, hyperglycemia, Influenza-like illness, tachycardia, and upper respiratory tract infection. Olmesartan does not cause cough more frequently than placebo does.[2] This medication may rarely cause a serious side effect called angiodema. Olmesartan may cause birth defects or fetal death if pregnant.


The olmesartan molecule includes one tetrazole group (a 5-member heterocyclic ring of four nitrogen and one carbon atom) and one imidazole group (a 5-membered planar heterocyclic aromatic ring of two nitrogen and three carbon atoms, classified as an alkaloid).

Mechanism of action

Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking binding rather than synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.


Do not use non-prescription products that contain stimulants; including diet pills, and cold medicines. Consult your doctor before taking any potassium supplements, including salt substitutes.

Dosage and administration

The usual recommended starting dose of olmesartan is 20 mg once daily. The dose may be increased to 40 mg after 2 weeks of therapy, if further reduction in blood pressure is desirable. Doses above 40 mg do not appear to have greater effect, and twice-daily dosing offers no advantage over the same total dose given once daily.[1] No adjustment of dosage is typically necessary for advanced age, renal impairment, or hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g., patients treated with diuretics), olmesartan should be initiated with caution; consideration should be given to use of a lower starting dose in such cases.[1] If blood pressure is not controlled by Benicar alone, a diuretic may be added. Benicar may be administered with other antihypertensive agents. Benicar may be administered with or without food.[1]


Metabolism and excretion


Benicar HCT is the brand name of a medication containing olmesartan medoxomil in combination with hydrochlorothiazide, a thiazide diuretic. Three dosage combinations are available: 20 mg or 40 mg of olmesartan medoxomil combined with 12.5 mg of hydrochlorothiazide, or 40 mg of olmesartan medoxomil combined with 25 mg of hydrochlorothiazide.

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


es:Olmesartán it:Olmesartan hu:Olmezartán

  1. 1.0 1.1 1.2 1.3 RxList Inc. (05 July 2007). "Benicar (olmesartan medoxomil)". RxList Inc. Retrieved 22 July 2010.  Check date values in: |date= (help); External link in |publisher= (help)
  2. "BENICAR Perscribing Information" (PDF). Retrieved 2009-08-26.